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Background
Activation of soluble guanylate cyclase (sGC) by BAY 58-
2667 is independent of nitric oxide (NO) and is potenti-
ated by oxidation or removal of the heme prosthetic
group [1]. This compound will displace heme from sGC
but only at concentrations several orders of magnitude
higher than those which activate the enzyme [2]. There-
fore the nature of the interaction of BAY 58-2667 with
sGC, the mechanism of activation, and the role of heme-
displacement under physiological conditions is of consid-
erable interest.
Materials and Methods
Scintillation proximity assay (SPA) technology avoids the
need for separation of bound and free radioliagand, ena-
bles the real-time study of binding kinetics, and is partic-
ularly well suited to soluble receptor proteins. Therefore
we investigated the feasibility of utilizing this methodol-
ogy in the characterization of binding of the heme-inde-
pendent activator BAY 58-2667 to sGC.
Results
Binding assays were configured using Protein A coated
SPA beads, an anti-sGC antibody, purified bovine lung
sGC and [3H]BAY 58-2667. Binding was dependent on
the presence of both antibody and sGC. A number of dif-
ferent antibodies and sources of sGC were investigated
and concentrations optimized to maximize specific bind-
ing (defined as that displaced by a 1000-fold excess of
non-radioactive BAY 58-2667). Specific binding was satu-
rable and reversible. Saturation data was best-fit with a
single-site model and a Kd of approx 2 nM which is signif-
icantly higher than EC50 values derived from relaxation
of vascular preparations in-vitro by ourselves and others
[1]. Maximum binding was approximately 1000 cpm.
Kinetic experiments revealed a mono-exponential dissoci-
ation phase. No significant competition of [3H]BAY 58-
2667 was observed between heme-dependent sGC activa-
tors such as YC-1 in the absence or presence of an NO-
donor. Likewise, a range of guanine nucleotides were
tested for their ability to influence binding of [3H]BAY 58-
2667 and no effect was observed.
Conclusion
SPA technology is a convenient method to study the inter-
action of sGC activators with the enzyme. Binding mirrors
functional effects but appears of lower affinity than
expected from functional measurements in vascular prep-
arations. The reasons for this discrepancy will be the sub-
ject of future investigation.
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